More Clinical Articles


Empowering Patients

Ulrich Neumann, (Aug 5, 2014)

The need for disruptive innovation in pharma has reached a precipice. In order to compete in the era of stratified medicine, cost-effectiveness considerations, and overall patient empowerment, the industry must rethink every aspect of the drug development continuum.

Some Front Row Perspectives on Patient Centricity

Paul Ivsin, (Aug 4, 2014)

"And that is quite likely the biggest barrier to advocates of patient centered clinical trials today: not that they will be resisted, but that their message will be co-opted and their efforts shunted into high-visibility but low-impact initiatives".

The Patient Centricity “Fad” and the Token Patient

Paul Ivsin, (Jul 30, 2014)

Embracing the concept of patient centricity does not guarantee substantial patient-centred change, particularly in the area of patient-centred trials.

Management of Patient Adherence in Clinical Trials Using Electronic Monitoring

John Musaus, (Jul 25, 2014)

Automatic adherence measurement through electronic compilation of drug dosing histories plays a key role in achieving and maintaining patients’ adherence to prescribed therapies.

Which Patients Are We Centred On?

Paul Ivsin, (Jul 24, 2014)

Paul Ivsin explains how our attempts to make clinical trials more patient-friendly have, for the most part, been subverted by the need to collect more comprehensive and more patient-relevant data, which can prove burdensome to the patient.

Digitization on trial

Nick de Cent, (Jul 18, 2014)

Clinical trials represent one important area where digitization is set to transform the pharma landscape, as social networks bring faster and more targeted recruitment of participants, writes Nick de Cent.

3D printing set to revolutionize pharma

Zuzanna Fimińska, (Jul 15, 2014)

3D printing is revolutionizing pharma by allowing new substances to be tested directly on human tissues, and by changing the economies of scale, whereby any drug can be cost effective.

VIDEO: Cancer survivor Jack Whelan speaks on how pharma can become more patient centric

Izzy Gladstone, (Jul 14, 2014)

Jack Whelan, ePatient and clinical trial proponent on how pharma needs to push the regulatory boundaries to fully engage with the patient and how a strict regulatory environment is hampering meaningful dialogue between pharma and the patient

Slashing the cost of clinical trials

Zuzanna Fimińska, (Jun 10, 2014)

It is a truth universally acknowledged that in this tough payer climate, pharma must slash costs. Software companies offer opportunities to streamline the clinical trial process from design to analysis, promising to save the industry at least US$3.7billion across phase II and phase III trials.
Access and Evidence

Big Data Will Make Clinical Trials Obsolete

Zuzanna Fimińska, (Apr 24, 2014)

Clinical trials as we know it are over. Their annual cost is unsustainable and solutions that curtail these expenses must be put in place. Luckily, big data offers unprecedented opportunities that will revolutionize research.